Clinical Trial Update: Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL [Phase 2]

View source ↗

Summary

This entry notes a Phase 2 clinical trial at the University of Cologne evaluating the combination of methotrexate, tafasitamab, lenalidomide, and rituximab in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• METHOTREXATE (METHOTREXATE)
• Rituximab (rituximab)
• tafasitamab (tafasitamab)

Snippet

Sponsor: University of Cologne | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: RECRUITING